Income statement, balance sheet and cash flow statement for the last 9 fiscal years, taken from the XBRL data 10x Genomics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2017
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
71.1
146
246
299
490
516
619
611
643
Cost of revenue
10.6
28.7
61
58.5
74.1
120
209
196
199
Gross profit
60.5
118
185
240
416
396
409
414
444
Research and development
32.2
47.5
83.1
123
212
266
270
265
239
Selling, general and administrative
46.7
87.9
131
202
258
298
343
344
316
Operating expenses
78.9
228
215
775
469
564
675
609
505
Operating income
-18.4
-111
-30.6
-534
-52.3
-168
-265
-195
-61
Interest expense
0.81
2.41
3.08
1.68
0.87
0.48
0.03
0
0
Interest income
0.31
1.02
2.81
1.53
0.21
6.65
16.9
18.9
20
Other non-operating income
-0.37
-1.63
-0.46
-0.33
-1.46
5.97
16.6
16.9
21.1
Pre-tax income
-18.7
-112
-31
-534
-53.7
-162
-249
-178
-39.9
Income tax
0.02
0.09
0.22
8.26
4.51
4.03
6.34
4.93
3.64
Net income
-18.8
-112
-31.3
-543
-58.2
-166
-255
-183
-43.5
EBITDA
-14.1
-107
-23.5
-520
-31.1
-143
-230
-159
-24.8
EPS, basic
-1.62
-8.40
-0.80
-5.37
-0.53
-1.46
-2.18
-1.52
-0.35
EPS, diluted
-1.62
-8.40
-0.80
-5.37
-0.53
-1.46
-2.18
-1.52
-0.35
Shares, basic (weighted)
11.6
13.4
39.1
101
110
114
117
120
125
Shares, diluted (weighted)
11.6
13.4
39.1
101
110
114
117
120
125
Balance sheet
FY2017
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
47.9
65.1
424
664
587
220
359
344
474
Short-term investments
0
210
29.4
49.3
49.4
Receivables
28.1
33.4
51.2
85.3
104
115
87.9
47
Inventory
8.57
15.3
30
60
81.6
73.7
83.1
56.3
Other current assets
4.5
8.03
13
13.9
16.6
18.8
19.4
22.2
Total current assets
106
481
774
748
635
596
584
684
Property, plant and equipment
11.1
48.8
72.8
169
289
280
253
227
Lease right-of-use assets
0
47
60.9
69.9
65.4
57.3
60.5
Goodwill
0
4.51
4.51
4.51
4.51
4.51
Intangible assets
0.64
22.4
22.4
25.4
22.9
16.6
15.7
62.3
Other non-current assets
1.94
23.9
4.32
3.32
2.39
3.06
4.13
2.91
Total assets
124
606
929
1,019
1,029
965
919
1,041
Accounts payable
8.79
13
4.71
17.4
21.6
15.7
12.9
12.7
Accrued liabilities
7.05
12.4
15.4
31.6
32.7
30.1
33.6
42.5
Deferred revenue
2.4
3.3
4.47
5.34
7.87
13.2
20.7
23.9
Short-term debt
4.19
9.88
0
Total current liabilities
32.4
63
118
110
131
127
118
153
Long-term debt
25.5
19.8
0
Lease liabilities
0
57
76.8
86.1
83.8
73.3
73.4
Other non-current liabilities
0.77
1.93
3.93
8.24
2.98
4.28
5.03
6.47
Total liabilities
101
186
190
201
223
224
209
245
Total debt
29.7
29.7
0
Paid-in capital
11.2
682
1,544
1,681
1,839
2,026
2,178
2,307
Retained earnings
-231
-262
-805
-863
-1,029
-1,284
-1,467
-1,511
Other comprehensive income
-0.04
-0.05
-0.05
0.02
-4.34
-0.43
-0.49
0.23
Shareholders' equity
-113
-220
420
739
818
806
741
710
796
Total equity
-113
-220
420
739
818
806
741
710
796
Total liabilities and equity
124
606
929
1,019
1,029
965
919
1,041
Shares outstanding
14.5
96.2
108
113
115
119
122
128
Cash flow statement
FY2017
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-18.8
-112
-31.3
-543
-58.2
-166
-255
-183
-43.5
Depreciation and amortization
4.31
3.91
7.07
14
21.1
25.4
35.5
35.9
36.2
Stock-based compensation
1.66
2.66
13.3
48.6
96
137
167
141
109
Deferred income tax
-0.01
0.08
-0.69
0.14
-0.45
0.71
-0.31
Change in receivables
-5.13
-14.7
-5.28
-17.8
-34
-18.9
-10.6
27
41.3
Change in inventory
-2
-3.73
-6.7
-14.6
-30.1
-21.2
7.87
-9.78
28
Change in payables
3.03
2.59
4.9
-7.77
11.1
5.86
-6.02
-3.35
-2.13
Cash from operations
-10.7
-76.4
34.6
-218
-21.4
-33.6
-15.2
6.66
136
Capital expenditures
-3.76
-6.28
-42.7
-36.7
-101
-132
-48.6
-12.4
-5.94
Acquisitions
0
0
-5.45
-4
0
0
Purchases of investments
0
0
-283
0
-48.9
-123
Sales and maturities of investments
0
0
18.5
82.8
25.8
125
Cash from investing
-3.76
-6.71
-42.8
-38.4
-107
-351
133
-32.6
-13.4
Debt issued
19.5
0
0
Debt repaid
-0.7
0
-31.3
0
0
Stock issued
1.09
0
411
482
0
0
Share buybacks
-0.08
Cash from financing
20.6
105
415
469
35.3
15.8
13.7
10.9
6.8
Exchange rate effect
-0.01
-0.02
-0.05
-0.46
0.23
-0.04
-0.03
-0.16
0.48
Net change in cash
6.11
22.2
406
212
-92.6
-369
132
-15.2
130
Free cash flow
-14.5
-82.7
-8.12
-255
-123
-165
-63.8
-5.73
130
Interest paid
0.66
1.82
2.25
1.67
1.22
0.84
0.44
0
0
Income taxes paid
0.01
0.02
0.28
8.66
3.93
4.93
5.64
2.39
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $85.71 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
70.0%
Gross profit / revenue.
Operating margin
-14.3%
Operating income / revenue.
EBITDA margin
-7.8%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-12.1%
Pre-tax income / revenue.
Net margin
-12.2%
Net income / revenue.
FCF margin
19.7%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
20.6%
Cash from operations / revenue.
Return on equity (ROE)
-9.1%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-7.3%
Net income / average total assets.
Return on invested capital (ROIC)
-21.6%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
36.8%
Research and development expense / revenue.
SG&A / revenue
48.1%
Selling, general and administrative expense / revenue.
Stock-based pay / revenue
16.0%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
0.9%
Capital expenditures / revenue.
D&A / revenue
6.5%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
5.2%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
7.6%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
16.6%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
7.1%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
3.9%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y
13.1%
Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Operating cash flow growth, 1y
1,942.0%
Operating cash flow vs the same period a year earlier. Only from a positive base.
Book value growth, 1y
12.1%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-0.4%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
1.5%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
13.4%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
0.4%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
2.3%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
3.6%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
3.1%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
4.3%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
5.69x
Current assets / current liabilities.
Quick ratio
5.06x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
4.66x
(Cash + short-term investments) / current liabilities.
Days inventory + days sales outstanding - days payables.
Capex / operating cash flow
4.4%
Capital expenditures / cash from operations, when that is positive.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$0.58
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$4.75
Revenue / diluted weighted shares.
FCF per share
$0.93
Free cash flow / diluted weighted shares.
Operating cash flow per share
$0.98
Cash from operations / diluted weighted shares.
Book value per share
$6.35
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
18.1x
Market cap / revenue.
P/B
13.5x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
14.7x
Market cap / tangible book value, when positive.
P/FCF
92.0x
Market cap / free cash flow. Only when free cash flow is positive.
P/OCF
87.9x
Market cap / cash from operations, when positive.
EV/Sales
17.2x
Enterprise value / revenue.
EV/FCF
87.4x
Enterprise value / free cash flow, when both are positive.
FCF yield
1.1%
Free cash flow / market cap.
Earnings yield
-0.7%
Net income / market cap (the inverse of P/E).
What was 10x Genomics, Inc.'s revenue in fiscal 2025?
10x Genomics, Inc. reported revenue of $642.8M for fiscal 2025, 5.2% higher than the year before.
Was 10x Genomics, Inc. profitable in fiscal 2025?
No. It reported a net loss of $43.5M.
How much free cash flow did 10x Genomics, Inc. generate in fiscal 2025?
Cash from operations of $136.1M minus capital expenditures of $5.9M left free cash flow of $130.1M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.